Frontier Medicines, located in South San Francisco, CA and Boston, MA, is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable. We are deploying our technologies in chemoproteomics, covalent drug discovery, and machine learning to develop a pipeline of groundbreaking medicines against the most important drivers of disease. Our lead program targets both the activated and inactive forms of KRAS G12C, a validated driver in a number of cancers that until recently has been undruggable. Our pipeline embodies our vision of bolding advancing science to defeat disease, starting with cancer.
Location: United States, California, San Francisco
Employees: 51-200
Total raised: $235.5M
Founded date: 2018
Founders name: Chris Varma
Founders Related Locations: United States, California, San Francisco
Investors 6
| Date | Name | Website |
| 18.05.2023 | MPM Capita... | mpmcapital... |
| - | DCVC | dcvc.com/ |
| - | RA Capital... | racap.com |
| - | Droia Onco... | droiaventu... |
| - | Berkeley C... | berkeleyca... |
| - | MPM BioImp... | mpmbioimpa... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 27.02.2024 | Series C | $80M | - |
| 20.07.2021 | Series B | $88.5M | - |
| 25.06.2019 | Series A | $67M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | Chris | Varma | Co-Founder... | linkedin.c... | - | - |
Mentions in press and media 23
| Date | Title | Description |
| 25.06.2024 | Frontier Medicines Appoints Gerardo Ubaghs as Chief Financial Officer and Announces $20 Million Series C Extension | Gerardo Ubaghs brings high-profile global biopharma strategic and capital markets experience as newly appointed Chief Financial Officer (CFO)Company adds $20 million to close oversubscribed Series C totaling $100 millionFinancing supports d... |
| 06.03.2024 | Frontier Medicines to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2024 | - |
| 27.02.2024 | Frontier Medicines: Oversubscribed $80 Million Funding Round Raised To Support Progress of Clinical-Stage Pipeline | Frontier Medicines – a precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets – announced the closing of an oversubscribed $80 million Series C f... |
| 26.02.2024 | Retail investors have been clamoring to invest in AI. With Fundrise, there’s now a path into private AI juggernaut Anthropic. | The old saying goes something like this: If you can’t get in the front door, go through the back, and if you can’t get in through the back door, find a window. Now retail investors have found the window to get in on hot AI startup Anthropic... |
| 25.02.2024 | Frontier Medicines Receives $80M in Series C Financing | Frontier Medicines Corporation, a Boston, MA- and San Francisco, CA-based precision medicine company developing therapies against otherwise undruggable disease-causing targets, received $80M in Series C funding. The round, which brought the... |
| 23.02.2024 | Frontier Medicines Secures $80 Million for Clinical-Stage Pipeline | Frontier Medicines, a precision medicine company, has successfully closed an oversubscribed $80 million Series C financing round. This funding will propel the progress of their clinical-stage pipeline, with a focus on the first-in-class dir... |
| 23.02.2024 | Frontier Medicines Inks $80M Series C | BOSTON, MA, Frontier Medicines today announced the close of an oversubscribed $80 million Series C financing. >> Click here for more funding data on Frontier Medicines >> To export Frontier Medicines funding data to PDF and ... |
| 22.02.2024 | Galapagos kondigt 2023 jaarresultaten en vooruitzichten 2024 aan | Financiële kerngetallen voor het hele jaar 2023: Netto groepsomzet van €783,5 miljoen in 2023, inclusief €112,3 miljoen nettoverkopen voor Jyseleca® Geldmiddelen en kortlopende financiële investeringen van €3,7 miljard per 31 december 2023 ... |
| 22.02.2024 | Frontier CEO weathers 'one of the hardest financings' of his career to close $80M series C | Frontier Medicines has just closed a $80 million fundraising, but, according to CEO Chris Varma, Ph.D., corralling the capital was, in his own words, harder than the bleakest days of the Great Recession. “I've been either an investor or an ... |
| 22.02.2024 | Galapagos announces full year 2023 results and outlook for 2024 | Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023 Operational cash burni of €414.8 million, within... |
Show more